Homologous boosting with adenoviral serotype 5 HIV Vaccine (rAd5) vector can boost antibody responses despite preexisting vector-specific immunity in a randomized phase I clinical trial
Uzma N. Sarwar, Laura Novik, Mary E. Enama, Sarah A. Plummer, Richard A. Koup, Martha C. Nason, Robert T. Bailer, Adrian B. McDermott, Mario Roederer, John R. Mascola, Julie E. Ledgerwood, Barney S. Graham, Elizabeth Adams, Nina Berkowitz, Joseph Casazza, Pamela Costner, Ingelise Gordon, Cynthia Starr Hendel, Lasonji Holman, Brenda LarkinSusan Leitman, Floreliz Mendoza, Jamie Saunders, Sandra Sitar, Brandon Wilson, Kathryn Zephir, Michelle Conan-Cibotti, Hope DeCederfelt, Judith Starling, Phyllis Renehan, Meghan Kunchai, Ly Diep, Olga Vasilenko, Galina Yamshchikov
Research output: Contribution to journal › Article › peer-review
Dive into the research topics of 'Homologous boosting with adenoviral serotype 5 HIV Vaccine (rAd5) vector can boost antibody responses despite preexisting vector-specific immunity in a randomized phase I clinical trial'. Together they form a unique fingerprint.